#USA #Miami #DCN Dx #Patient Access #BioSouthTech

DCN Dx Expands Access to Diverse Patient Populations with BioSouthTech Acquisition

In a significant step towards enhancing research capabilities in the healthcare sector, DCN Dx has announced its acquisition of BioSouthTech, a prominent provider of human biospecimens based in the Miami area. This merger is set to greatly expand DCN Dx's access to diverse patient populations across Latin America, with an established collection network spanning South America and the Caribbean.

The integration of BioSouthTech's capabilities aligns with DCN Dx's commitment to supporting drug and diagnostic research with a focus on patient representation. As patients' demographics are critical in developing diagnostic tests, this acquisition allows DCN Dx to enhance its sample bank and broaden its procurement options for crucial research areas such as oncology, neurology, and autoimmune diseases.

Charlie Mamrak, CEO of DCN Dx, emphasized that the goal of this acquisition is to provide researchers with improved access to varied patient backgrounds, allowing for a more accurate reflection of the populations intended to benefit from new diagnostic tools. By incorporating BioSouthTech's extensive collection of banked specimens, DCN Dx can now offer a more comprehensive range of patient specimens essential for testing the effectiveness of new diagnostics across different demographic groups.

Jim Boushell, the senior vice president of biospecimens at DCN Dx, highlighted the critical importance of diversity in patient representation. He remarked, "You can't develop a test for everyone on data from a few. For over two decades, I have observed the evolution of technology based on data that inadequately represents the patients for whom those tests are designed. The acquisition of BioSouthTech allows developers to tap into more diverse patient populations, including those who have not yet received treatment, thereby enhancing the evidence supporting their innovations."

From now on, clients of DCN Dx can conveniently request characterized tissue and matched sets from the vast resource library, either readily available off the shelf or tailored through prospective collections aligned with specific protocols. This initiative not only addresses existing gaps in patient representation in research but also opens new opportunities for studies into various diseases by expanding the diversity of participants.

The network already encompasses patients from different ancestries and regions, and there are plans for further geographical expansion and increased cohort diversity anticipated in early 2027.

This acquisition is poised to revolutionize the landscape of diagnostic test development by ensuring that the underlying data reflects the rich diversity of patient populations. Pharma companies and diagnostic developers relying on DCN Dx's services can now be assured that their research is grounded in data that encompasses the full spectrum of potential patients.

As DCN Dx takes this next step in its evolution, the focus remains on delivering high-quality biospecimen services rooted in diversity and patient-centric research philosophies. To learn more about DCN Dx's biospecimen offerings, visit dcndx.com/services/biospecimen.

About DCN Dx

DCN Dx is a leader in the field of diagnostic development, boasting over 20 years of experience in bringing diagnostic tests from conception to commercial success. With a blend of services that includes offering an immunoassay Contract Development and Manufacturing Organization (CDMO), an in vitro diagnostics (IVD)-dedicated Contract Research Organization (CRO), and a biospecimen business, DCN Dx assists developers in connecting with diverse patient populations and compliant specimen sourcing that adheres to their study protocols and intended uses. All direct collections operate under Institutional Review Board (IRB) and Independent Ethics Committee (IEC) oversight, ensuring standardized procedures are followed alongside comprehensive clinical and demographic data and chain-of-custody documentation. Based in Carlsbad, California, DCN Dx is dedicated to advancing healthcare through innovative partnerships in research and diagnostics.